Division of Health Protection Technologies, Territorial and Production Systems Sustainability Department, ENEA, Rome, Italy.
Department of Pediatrics and Infantile Neuropsychiatry, Pediatric Gastroenterology and Liver Unit, Sapienza University of Rome, Italy.
Dig Liver Dis. 2017 Nov;49(11):1201-1210. doi: 10.1016/j.dld.2017.08.017. Epub 2017 Aug 10.
Necroptosis is an inflammatory form of programmed cell death requiring receptor-interacting protein kinase 3 (RIP3) and mixed lineage kinase domain-like protein (MLKL).
The aim of this study is to examine in depth in vitro and ex vivo the contribution of necroptosis to intestinal inflammation.
In vitro: we used an intestinal cell line, HCT116RIP3, produced in our laboratory and overexpressing RIP3. Ex vivo: intestinal mucosal biopsies were taken from patients with inflammatory bowel disease (IBD) (20 with Crohn's disease; 20 with ulcerative colitis) and from 20 controls.
RIP3-induced necroptosis triggers MLKL activation, increases cytokine/alarmin expression (IL-8, IL-1β, IL-33, HMGB1), NF-kBp65 translocation and NALP3 inflammasome assembly. It also affects membrane permeability by altering cell-cell junctional proteins (E-cadherin, Occludin, Zonulin-1). Targeting necroptosis through Necrostatin-1 significantly reduces intestinal inflammation in vitro and in cultured intestinal explants from IBD.
We show for the first time in vitro and ex vivo that RIP3-driven necroptosis seriously affects intestinal inflammation by increasing pMLKL, activating different cytokines and alarmins, and altering epithelial permeability. The inhibition of necroptosis causes a significant decrease of all these effects. These data strongly support the view that targeting necroptosis may represent a promising new option for the treatment of inflammatory enteropathies.
细胞程序性坏死是一种炎症形式的细胞死亡,需要受体相互作用蛋白激酶 3(RIP3)和混合谱系激酶结构域样蛋白(MLKL)。
本研究旨在深入研究细胞程序性坏死对肠道炎症的贡献。
在体外:我们使用了我们实验室制备的过表达 RIP3 的肠细胞系 HCT116RIP3。在体外:我们从炎症性肠病(IBD)患者(20 例克罗恩病,20 例溃疡性结肠炎)和 20 例对照中获取了肠黏膜活检。
RIP3 诱导的细胞程序性坏死触发 MLKL 激活,增加细胞因子/警报素的表达(IL-8、IL-1β、IL-33、HMGB1),NF-κBp65 易位和 NALP3 炎性体组装。它还通过改变细胞间连接蛋白(E-钙黏蛋白、紧密连接蛋白、Zonulin-1)来影响膜通透性。通过 Necrostatin-1 靶向细胞程序性坏死可显著减轻体外和 IBD 培养肠外植体中的肠道炎症。
我们首次在体外和体外证明 RIP3 驱动的细胞程序性坏死通过增加 pMLKL、激活不同的细胞因子和警报素以及改变上皮细胞通透性,严重影响肠道炎症。抑制细胞程序性坏死会显著减少所有这些影响。这些数据强烈支持靶向细胞程序性坏死可能是治疗炎症性肠病的一种有前途的新选择的观点。